| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3891 |
| Trial ID | NCT06429800 |
| Disease | Lupus Nephritis | Systemic Lupus Erythematosus |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | ATA3219 |
| Generation | 2th |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell (CAR T) Therapy, in Subjects With Lupus Nephritis |
| Year | 2024 |
| Country | United States |
| Company sponsor | Atara Biotherapeutics |
| Other ID(s) | ATA3219-AEC-104 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||